29 results about "Soma" patented technology

The invention provides a marker of spinal cord functional neural precursor cells, a detection method and a sorting method, and belongs to the technical field of biological medicine. The invention provides application of a marker detection reagent in preparation of a kit for detecting spinal cord functional neural precursor cells. The invention further provides a sorting-based method for separating the SFNPCs cells, and the cells are sorted through the Marker of the specific SFNPCs, so that the cell purity of the SFNPCs is remarkably improved, the difference between batches is reduced, and a high-purity and homogeneous SFNPCs cell population is obtained. The survival rate of the SFNPCs cells separated and subcultured to the P9 generation by the method disclosed by the invention is more than 85%, and the SFNPCs cells have a good treatment effect on a spinal cord injury model.

The invention discloses a fruit image classification method based on a wide area network dendritic neuron model, and the method comprises the steps: achieving the multi-scale feature extraction through parallel 1 * 1, 3 * 3 and 5 * 5 convolution and pooling branches, carrying out the fusion convolution, LeCannTanh activation and batch normalization, generating a feature representation through the combination of global average pooling and a lightweight feedforward network, and carrying out the classification of fruit images through the feature representation. And self-adaptive nonlinear classification is realized by means of synaptic-dendritic-somatic cell-axon hierarchical processing of dynamic dendritic neurons. Experimental results show that the method has the advantages of high precision, high robustness and low time delay in scenes with complex backgrounds, large intra-class differences and small samples, and is suitable for industrial applications such as intelligent sorting and automatic quality inspection.

The present application relates to a nutritional composition, a product comprising the same and use thereof in the preparation of a product for alleviating synaptic plasticity impairment of a body. The nutritional composition comprises: docosahexaenoic acid (DHA) and / or a metabolic precursor thereof, sodium hyaluronate (SH), and lactoferrin (LF). When docosahexaenoic acid (DHA), sodium hyaluronate (SH) and lactoferrin (LF) are used in combination, they can synergistically alleviate synaptic plasticity impairment of a body, in particular, increase nerve growth factor (NGF) content and / or brain-derived neurotrophic factor (BDNF) content in PC12 cells of the body, and / or increase expression of synaptic-related proteins in PC12 cells of the body.

The application discloses an induction method for directional differentiation of neural stem cells into dopaminergic neurons, comprising the following steps: S1, activation and adhesion of NSCs; S2, directional induction of midbrain precursor cells; S3, directional induction of dopaminergic neurons; and S4, synaptic function maturation induction. The induction method for directional differentiation of neural stem cells into dopaminergic neurons can significantly improve the directional efficiency and lineage specificity of the midbrain precursor cells: by adding salvianolic acid B and icariin, and in cooperation with SHH, FGF8 and other induction factors, the midbrain lineage-specific signal pathway can be efficiently activated, the positive rate of the midbrain precursor cell marker LMX1A is increased to more than 76%, which is far better than 49% of the existing system, and abnormal differentiation of non-midbrain lineages is effectively inhibited.

Provided are cortical interneurons and other neuronal cells and in vitro methods for producing such cortical interneurons and other neuronal cells by the directed differentiation of stem cells and neuronal progenitor cells. The present disclosure relates to novel methods of in vitro differentiation of stem cells and neural progenitor cells to produce several type neuronal cells and their precursor cells, including cortical interneurons, hypothalamic neurons and pre-optic cholinergic neurons. The present disclosure describes the derivation of these cells via inhibiting SMAD and Wnt signaling pathways and activating SHH signaling pathway. The present disclosure relates to the novel discovery that the timing and duration of SHH activation can be harnessed to direct controlled differentiation of neural progenitor cells into either cortical interneurons, hypothalamic neurons or pre-optic cholinergic neurons. The present disclosure also relates to compositions of cortical interneurons, hypothalamic neurons or pre-optic cholinergic neurons, and their precursors, that are highly enriched and can be used in variety of application. These cells can be used therapeutically to treat neurodegenerative and neuropsychiatric disorders, and can be used for disease modeling and drug screening.

The invention belongs to the field of biomedical materials, and particularly relates to a hydrogel composite scaffold loaded with human spinal cord V3 precursor cells for spinal cord injury repair and a preparation method of the hydrogel composite scaffold. The hydrogel composite scaffold comprises hydrogel and human spinal cord V3 neural precursor cells, hydrogel is used as a carrier, the human spinal cord V3 neural precursor cells are loaded on the hydrogel, and the hydrogel is formed by oxidized hyaluronic acid and carboxymethyl chitosan through a Schiff base cross-linking reaction. The specific preparation method comprises the following steps: mixing the human spinal cord V3 neural precursor cells with hydrogel to obtain the hydrogel composite scaffold loaded with the human spinal cord V3 neural precursor cells. Therefore, the technical problems of low cell survival rate, non-uniform cell distribution and difficulty in controlling the cell differentiation direction in spinal cord injury repair in the prior art are solved.

Methods for identifying, isolating and enriching neural stem and progenitor cells (NSPC) such as ventricular radial glia, outer radial glia, astrocytes, pre-oligodendrocyte precursor cells, oligodendrocyte precursor cells, oligodendrocytes, early excitatory neurons, late excitatory neurons, bipotent glial progenitors, and inhibitory neurons are provided. These methods find use in transplantation, to eliminate specific cell subsets, for experimental evaluation, as a source of lineage and cell-specific products, and the like, for example for use in treating human disorders of the central nervous system (CNS).

The present invention relates to a method of generating an in vitro modular 3D brain tissue model (3D BTM) comprising: a. mixing 50,000 to 1,000,000 freshly splitted, single neurons (NE) and astrocytes (AS) or their precursor cells in a ratio of NE:AS = 1:3 to 10:1, followed by spinning down to introduce self-aggregation in low attachment conditions, without addition of exogenous matrices; b. treating cells obtained in step a. with a NOTCH signaling inhibitor for driving terminal neuron differentiation for at least 2 days; c. treating the cells obtained in step b. with at least one mitotic inhibitor to remove residual dividing cells for at least 3 days, thereby yielding a post-mitotic aggregated 3D culture of neurons and astrocytes; d. adding differentiated microglia (MG) to the culture obtained in step c. in a ratio of NE:MG = 1:1 to 20:1, to initiate migration of MG into the culture for 3-10 days; e. culturing the culture obtained in step d. in neuron media with addition of TGFβ1 and cytokines selected from the group comprising CSF1-R agonists to support microglia maintenance and proliferation for at least 2 weeks, thereby inducing formation of a modular in vitro 3D BTM culture.

The present application relates to the field of medical biotechnology, and provides a dopaminergic neuron precursor cell surface marker F3 and / or SSTR2, and high-purity dopaminergic neuron precursor cells are obtained by screening the dopaminergic neuron precursor cells using the marker, and the dopaminergic neuron precursor cells have a higher efficiency of differentiating into dopaminergic neurons.

Somatic instability (SI) in the mutant HTT allele is a high value therapeutic target for Huntington's Disease (HD). However, rates of SI and the speed of HD progression vary widely with inherited germline CAG repeat lengths across the HD patient population. Understanding this variability and projecting the treatable range of patients for SI-directed therapies is important to their design, preclinical development, and conferring optimal benefit to HD patients. A computational model and related method(s) track the percentage of healthy medium spiny neurons (MSNs) across the lifetime of HD patients. Changes in MSN survival are predicted based on an exemplary SI-directed interventional gene therapy. The range of treatable patients is also projected. The flexible framework provided by the computational model and related method(s) enables therapeutic performance prediction and projecting outcomes across the HD patient population and furthermore, serves as a valuable tool for defining the target populations for SI-directed therapies.

Disclosed herein are methods for generating dopaminergic neurons and organoids comprising thereof. Particularly, the disclosure relates to methods for generating dopaminergic neurons by differentiating stem or precursor cells into Achaete-scute family bHLH transcription factor 1 (Ascl1)-driven mesenchymal progenitor cells and then terminally differentiating the Ascl1-driven mesenchymal progenitor cells into dopaminergic neurons alone or alongside astrocyte and hematopoietic precursor cells.

The invention relates to a liquid dressing for skin and a preparation method of the liquid dressing. A film forming material of the liquid dressing comprises glial cell supernate. The neuroglial cells used in the invention are derived from neural stem cells which have been subjected to long-term in-vitro culture amplification, so that the obtained culture supernatant has the advantages of large scale, stable quality and mature technology, and a large number of liquid dressing products with stable and consistent quality standards can be provided in a short time; meanwhile, the supernate has good film-forming property and safety, contains a large number of human cell active components which are good in human body compatibility and beneficial to wound healing, and is suitable for large-scale batch production and application.

The invention relates to products and methods for transdifferentiating oligodendrocytes and / or oligodendrocyte precursor cells to neurons. The invention further relates to methods of treating central nervous system disorders and conditions.

The invention relates to products and methods for transdifferentiating oligodendrocytes and / or oligodendrocyte precursor cells to neurons. The invention further relates to methods of treating central nervous system disorders and conditions.

The invention relates to the technical field of biology, in particular to a medicine and application thereof. The drug is an exosome (DPSCs-Exos) derived from dental pulp stem cells (DPSCs-Exos). The DPSCs-Exos is given after acute cerebral apoplexy, so that sensory movement and cognitive function recovery after cerebral ischemia can be promoted. The DPSCs-Exos can improve ischemia for 45 minutes, and brain tissue injury and neurological function injury of animals after reperfusion for 28 days. The DPSCs-Exos promotes the expression increase of protein arginine methyltransferase (PRMT5) in oligodendroglia precursor cells (OPC), inhibits the expression of a differentiation inhibition factor 2 (ID2) through nucleation, promotes the OPCs to proliferate and differentiate into oligodendroglia cells (OL), and promotes the integrity repair of white matter. In addition, DPSCs-Exos can promote proliferation and migration of vascular endothelial cells and promote blood brain barrier repair.

The present invention relates to use of slow-releasing hydrogen sulfide organic donor ADT-OH drugs in the differentiation of neural precursor cells. ADT-OH can induce more directed differentiation of neural precursor cells into neurons and oligodendrocytes and less differentiation into astrocytes, promote the axon growth of neurons, and reduce the death of neural precursor cells, thereby providing a direction for the transplantation of neural precursor cells to repair damaged nerves. ADT-OH will likely become a new drug target for the clinical treatment of nervous system diseases.

Disclosed is a composition for supporting survival and differentiation of neural precursor cells (NPCs) grafted into a neurological injury or disease site, the composition comprising: (a) a gel forming molecule; and (b) a chemokine receptor type 5 (CCR5) antagonist. Also disclosed is a method of treating a neurological injury or disease of a subject, comprising (a) mixing NPCs with the composition as disclosed herein; and (b) administering a mixture of the NPCs and the composition into a neurological injury or disease site of the subject, to thereby support survival and differentiation of the NPCs. Also disclosed is use of a mixture of NPCs and the composition as disclosed herein in the manufacture of a medicament for treating a neurological injury or disease of a subject, wherein the mixture is to be administered into a neurological injury or disease site of the subject, to thereby support survival and differentiation of the NPCs. Further disclosed is a kit for use in supporting survival and differentiation of NPCs grafted into a neurological injury or disease site, the kit comprising: (a) the composition as disclosed herein; (b) artificial cerebral spinal fluid (a-CSF); (c) CaCl2; and (d) thrombin.

The invention relates to products and methods for transdifferentiating oligodendrocytes and / or oligodendrocyte precursor cells to neurons. The invention further relates to methods of treating central nervous system disorders and conditions.

The invention provides an in-vitro cerebral cortex intermediate neuron precursor cell population as well as a preparation method and application of the in-vitro cerebral cortex intermediate neuron precursor cell population. According to the cell population, the iNSC is taken as an initial cell to directionally differentiate to the neuroectoderm cell, so that neuroendoderm and neuromesoderm impurity cells generated in the differentiation process can be reduced, the cell differentiation direction is more accurate, and the differentiated cell purity is higher. The cell population can be used for the prevention, diagnosis and treatment of nervous system diseases.

The present disclosure provides a flexible biodegradable and resorbable brain (or other tissue) stimulation electrode for temporally regulated neuromodulation of neural precursor cells (NPCs), which may also be used for recording electrical signals in the brain or other tissue. Using the cathodally skewed electrochemical window of molybdenum and the volumetric charge transfer properties of a conductive polymer, the electrodes are designed with high charge injection capacity for the delivery of biphasic monopolar stimulation. These electrodes are biocompatible and can deliver an electric field sufficient for NPC activation for at least 7 days post implantation before undergoing resorption in physiological conditions., thereby eliminating the need for surgical extraction. The biodegradable electrode demonstrated its potential to be used for NPC based neural repair strategies.

This invention provides the use of dicyclohexanone oxaloyl dihydrazone in stroke medications and a stroke medication itself. The use includes the application of dicyclohexanone oxaloyl dihydrazone in the preparation of medications for treating stroke, particularly ischemic stroke. This invention effectively promotes myelin regeneration and neurological function repair in the very early post-stroke period (e.g., within 24 hours) by targeting and regulating the "ceruloplasmin-iron metabolism-myelin regeneration" axis. The specific mechanisms include upregulating ceruloplasmin expression in the brain, enhancing its ferrooxidase activity, promoting iron transport and reuse in the brain, thereby promoting the survival, differentiation, and myelination of oligodendrocyte precursor cells. Animal experiments show that stroke model mice exhibit significant improvement in neurological function as early as day 1 after administration, with a faster onset of action than existing technologies. This invention has the advantages of rapid onset of action, clear target, and comprehensive repair effects, and has promising clinical application prospects.

The present disclosure relates to a detection device and a detection system for movement direction. The detection device includes: a plurality of sensors, each sensor including a plurality of sensor units linearly arranged along a first direction; a first neuromorphic device including a first synaptic unit, a first dendritic unit, and a first soma unit, the first synaptic unit including a silent synapse and an excitatory synapse, the first soma unit processing the output of the first dendritic unit to generate a first output signal; a second neuromorphic device including a second synaptic unit including only excitatory synapses, a second dendritic unit, and a second soma unit, the second soma unit processing the output of the second dendritic unit to generate a second output signal; and a third neuromorphic device including a third synaptic unit, a third dendritic unit, and a third soma unit, the third synaptic unit including an inhibitory synapse that receives the second output signal and an excitatory synapse that receives the first output signal, the third soma unit processing the output of the third dendritic unit to generate a third output signal.

The application provides a dopamine nerve precursor cell freezing solution which is free of serum and animal-derived components, and contains a clinical-grade freezing base solution dextran sodium chloride injection, a non-osmotic cryoprotectant injection-grade human serum albumin (HSA) and an osmotic cryoprotectant injection-grade DMSO, wherein the mass concentration of the non-osmotic cryoprotectant is less than 10% and the mass concentration of the osmotic cryoprotectant is less than 15%, and the dopamine nerve precursor cell freezing solution further contains an additive capable of improving the recovery rate of dopamine nerve precursor cells. The dopamine nerve precursor cell freezing solution provided by the application has simple and clear components, can greatly reduce the damage to cells during the freezing process, significantly improve the recovery rate of cells after resuscitation, maintain the purity and the potential for continuous differentiation of the cells, and is suitable for the storage of clinical-grade dopamine nerve precursor cells at different differentiation stages.

The present disclosure provides compositions and methods for treating a mammalian subject for an ON neuropathies and / or reducing or ameliorating degeneration of axons and / or soma of RGCs. Aspects of the composition include a neuroprotective agent and a pharmaceutically acceptable excipient, where the neuroprotective agent inhibits HRH1 activity. A variety of ON neuropathies may be treated by practicing the methods, including retinal ganglion cell degeneration, glaucoma, optic neuritis, ON traumatic injury and other ON-related diseases.

Transplantation of inhibitory neuronal precursor cells can reactivate a targeted, time-limited critical phase plasticity stage in a receptor brain region. Restoration of such young plasticity creates a therapeutic environment that facilitates circuit recombination and has continuously proved that cognitive and dysfunction can be ameliorated. It is notable that the critical phase plasticity is sufficient to reactivate only by overexpression of Calb1 in adult inhibitory neurons by viral vectors, without the need for transplantation. Accordingly, described herein are methods and compositions for enhancing Calb1 expression as a therapeutic pathway to reactivate plasticity.

A method of shunting inhibition mechanism in a neuromorphic circuit is provided. The method comprises inputting excitatory signals to an artificial neuron soma having a resting membrane potential. Shunting conductances are input to the artificial neuron soma to multiply response to the excitatory signals in the artificial neuron soma, wherein the shunting conductances have a reversal potential approximately equal to the resting membrane potential of the artificial neuron, and wherein increasing the shunting conductances increases membrane conductance of the artificial neuron soma.

Compositions and methods for treating a mammalian subject for an optic nerve (ON) neuropathy and / or reducing or ameliorating degeneration of axons and / or soma of RGCs are provided. Aspects of the composition include a mammalian viral vector, comprising a murine γ-synuclein promoter, or functional fragment thereof, that promotes expression of a transgene specifically in retinal ganglion cells (RGCs), the promoter in operable linkage with an expression cassette encoding the transgene, wherein the expressed transgene inhibits activity of an expression product of an endogenous pro-neurodegenerative gene involved in an ER stress and / or UPR pathway that leads to axon or soma degeneration in the RGCs. Aspects of the methods include intravitreally administering the composition to treat the subject for the ON neuropathy. A variety of ON neuropathies may be treated by practicing the methods, including retinal ganglion cell degeneration, glaucoma, optic neuritis, ON traumatic injury and other ON-related diseases.

The present invention relates to a portable memory processing device for performing operations such as addition, subtraction, multiplication, and division of multiple digits in parallel, with the result stored in the same unit. The model and processing mode of the memory processing unit are based on P-type spiking neural networks. First, the numbers processed by the memory processing unit are stored in a unary system, in which the data are represented by spikes (or ones). Subsequently, the user enables the desired operation by activating the firing rules of the neurons. Finally, the resulting spikes, generated by the neurons, are stored in the neuron's soma.The activation mechanism of neurons and the storage process are performed in the same unit, eliminating the need for separate ALUs and memory, thus increasing processing speed. In current computing systems, data stored in memory is transferred to the ALU. This creates a bottleneck and generates high energy consumption. Therefore, our solution optimizes storage and processing within the same unit using unconventional mechanisms (neurons) to perform both operations.

To provide a method for generating and isolating midbrain dopamine neurons.SOLUTION: The present disclosure provides methods for producing midbrain dopamine neurons (mDA) and precursors thereof, mDA and precursors thereof produced by such methods, and compositions comprising such cells, and uses thereof for preventing and / or treating neurological disorders. The present disclosure further provides methods of isolating mDA and their precursors from cell populations using the novel surface markers. In certain embodiments, the cells are contacted with the at least one activator of FGF signaling for at least about 1 day. In certain embodiments, the cells are contacted with the at least one activator of FGF signaling for up to about 15 days. In a particular embodiment, the cells are contacted with the at least one activator of FGF signaling for about 5 days.SELECTED DRAWING: None